Remember meForgot password?
    Log in with Twitter
| Press Release

FLEX PHARMA SHAREHOLDER ALERT: Securities Fraud Lawsuit Filed Against Flex Pharma; Block & Leviton Encourages Shareholders to Contact the Firm

BOSTON, MA / ACCESSWIRE / June 29, 2018 / Block & Leviton LLP (, a securities litigation firm representing investors nationwide, reminds investors in Flex Pharma, Inc. ("Flex Pharma" or the "Company") (NASDAQ: FLKS) that Monday, August 20, 2018 is the deadline to seek lead plaintiff status in the pending securities class action against the Company and certain of its officers and directors.

The lawsuit, filed in the Southern District of New York (No. 1:18-cv-05493), alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (i) the Company overstated the viability and approval prospects for its product candidate FLX-787 for the treatment of ALS and CMT; and (ii) as a result, Flex Pharma's public statements were materially false and misleading at all relevant times.

On June 13, 2018, Flex Pharma announced that it planned to halt both the COMMEND and the COMMIT trials (the trials connected to "FLX-787"), citing oral tolerability concerns observed in both studies. On this news, FLKS stock plunged about 75%.

If you purchased or otherwise acquired FLKS securities between November 6, 2017 and June 12, 2018 and have questions about your legal rights or possess information relevant to this investigation, you are encouraged to contact Attorney John DeFelice at (888) 868-2385, by email at or by visiting

Block & Leviton LLP was recently ranked 4th among securities litigation firms by ISS for recoveries in 2017. The firm represents many of the nations' largest institutional investors and numerous individual investors in securities litigation throughout the country. Indeed, its lawyers have recovered billions of dollars for its clients.

This notice may constitute attorney advertising.


John DeFelice
(617) 398-5600 phone
155 Federal Street, Suite 400
Boston, MA 02110

SOURCE: Block & Leviton LLP

Latest News
Top News